Repatriated earnings tax charge hits Johnson & Johnson bottom line
This article was originally published in Clinica
Johnson & Johnson's decision to repatriate foreign earnings under the 2004 American Jobs Creation Act has resulted in a special charge of $789m in the fourth quarter. As a result, the group's quarterly earnings slipped 34% to $1.2bn.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.